The accompanying table includes an updated version of the ETFI Highly Defensive PerformIdex of 40 companies based in the U.S., Canada, and Europe with market caps over $10B, which are the leaders by market cap in their defensive industry groups. The updates include removing retail exposure at CVS Caremark (CVS) and Tesco (TSCDY) in favor of keeping Wal-Mart (WMT) as the major beneficiary of a trade-down effect and mass merchant discounter, which integrates groceries, pharmacy, everyday clothing, c
The accompanying table presents an analysis and statistics for the 28 healthcare ETFs listed at the Yahoo! Finance ETF Center. As a group, the healthcare ETFs outpaced the overall market in the past year by more than 10%, posting an average loss of 26.5% compared to a loss of 37.4% for the S&P 500 SPDR ETF (SPY). The best performing healthcare ETF was the Biotech HOLDRs (BBH), thanks to a buyout bid for top holding Genetech (DNA) and solid earnings results this year for the number two position, Amgen (AMGN).
The accompanying table presents my 60 defensive growth stock picks at the recently launched online investing site Inner8.com , which I wrote about yesterday. My picks are focused on healthcare and consumer staples, along with some cash rich tech companies such as Microsoft (MSFT). My picks include companies across the entire spectrum of market cap and risk in the biotech industry, ranging from top performers such as Amgen (AMGN) and Celgene (CELG) to small and micro-cap picks such as Discovery Labs (DSCO),
Medical Stocks have been showing continued strength with the
overall market uncertain if the correction has ended or the current uptrend is
just a pause before another leg down for the markets. Celgene Corp is one of
the strongest of the medical/biological companies that should continue to
appreciate in value.
Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of innovative therapies to treat cancer and immune-inflammatory related diseases in Europe and the United States. Its primary commercial stage products include REVLIMID (lenalidomide) for the treatment in combi...
Financials led stocks down with Lehman leading the way as it attempted to deny rumors that it is raising $3 to $4 billion. Macke says LEH is trading “like a stuck pig” and while he doesn’t think it is another Bear Stearns, he wouldn’t buy the stock. Najarian observed put activity in LEH and XLF and high volatility. Finerman says LEH will have to approach the markets to get liquidity even though this will hurt the stock. Ada
Recap of CNBC's Fast Money, Monday June 2. Click on a stock ticker for more analysis.
<!---->
Down Time: Wachovia (WB), Goldman Sachs (GS) and Citigroup (C), KeyCorp (KEY), Bank of New York Mellon (BK)
On news Lehman Brothers, Morgan Stanley and Merrill Lynch were downgraded and Wachovia’s Chief KevinThompson was dismissed, financials and the Dow faltered. Jeff Macke said when the S&P 500 didn’t surpass 1400, it sold off. Jeff Macke would by GS at $150 and Citi at $20. Pete Najarian is concerned about BK and KEY and discussed unusual options volume in the stocks.
Recap of CNBC's Fast Money, Wednesday May 28.
<!---->
Oil Rebounds: AMR (AMR), UAL (UAUA), Alpah Natural Resources (ANR), Consol Energy (CNX), Massey (MEE), Eastman Chemical (EMN), Sasol (SSL), First Solar (FSLR), Energy Conversion Deviced (ENER)
Macke said Nigerian rebels were a convenient excuse for oil to go higher, and that the upward trend will last. Guy Adami likes AMR and noted there is talk of a deal between UAL and U.S. Airways. Macke would sell the airline rally and Pete Najarian says oil will have to drop before airlines recover. Pete Najarian is bullish on natural gas and co
Label expansion on Revlimid and Vidaza into other hematological cancers should offer upside for Celgene. We believe all this is currently reflected in the stock.
Readers of this space know that, for a plethora of reasons, companies in the pharmaceutical and biotech sectors are not my preferred stocks, but there are exceptions. And with the above in mind, Celgene is worth a review.
Celgene (NASDAQ: CELG) develops and markets drugs to treat cancer, immunological disorders and other diseases. The company's research concentrates on small molecule compounds that inhibit tumor necrosis factor alpha (TNFa) production or aberrant estrogen production, or that may regulate kinases and ligases (enzymes).
High velocity, high volatility and favorable risk / reward profile
for comparative analysis, other high velocity / high volatility stocks with favorable risk / reward profiles, and stocks with potential for short-term reversals, visit:
Data powered by QuoteMedia.
All Rights Reserved.
Data delayed 15 to 20 minutes unless otherwise indicated.
Terms of Use.
None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.
